HBIO
Harvard Bioscience, Inc.
Set alert
- YTD
- +32.84%
- 1 year
- +41.27%
- Open
- 8.80
- Prev close
- 8.80
- Mkt cap
- 40.52M
- Vol
- 23.17K
- Avg vol
- 19.26K
- EPS
- -2.31
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.80
- High
- 8.92
- Forward P/E
- 14.00
- Beta
- 1.31
- Short ratio
- 2.66
- Inst. own
- 75.99%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.30
- 200-d avg
- 3.04
- 1y target
- 6.25
Key statistics
- Market cap
- 91.59M
- Enterprise value
- 133.38M
- Trailing P/E
- 0.00
- Forward P/E
- 14.00
- PEG ratio
- 0.00
- Price / sales
- 0.94
- Price / book
- 1.40
- EPS (TTM)
- -0.33
- Beta
- 1.31
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -14.57%
- Revenue (TTM)
- 97.73M
- Revenue growth
- -13.40%
- Free cash flow
- 6.06M
- Total cash
- 4.57M
- Total debt
- 45.91M
- Return on equity
- -20.40%
- Shares outstanding
- 43.62M
- Short % of float
- 1.11%
- 50-day average
- 2.30
- 200-day average
- 3.04
Analyst view
Consensus: none
- Target (low)
- 5.50
- Target (mean)
- 6.25
- Target (high)
- 7.00
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.05.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | 0.05 | -0.02 | -0.07 | -140.00% |
| Aug 8, 2024 | Jun 1, 2024 | 0.05 | -0.03 | -0.08 | -160.00% |
| Aug 8, 2024 | Jun 1, 2024 | 0.05 | 0.00 | — | — |
| May 7, 2024 | Mar 1, 2024 | 0.02 | 0.02 | 0.00 | 0.00% |
| May 7, 2024 | Mar 1, 2024 | 0.02 | 0.00 | — | — |
| Mar 7, 2024 | Dec 1, 2023 | 0.05 | 0.01 | -0.04 | -80.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 22, 2023 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Apr 26, 2023 | Benchmark | main | — | Buy |
| Apr 26, 2023 | Keybanc | main | — | Overweight |
| Mar 10, 2023 | Benchmark | reit | — | Buy |
| Nov 9, 2022 | Keybanc | main | — | Overweight |
| Aug 5, 2022 | Keybanc | main | — | Overweight |
About Harvard Bioscience, Inc.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- harvardbioscience.com
News
- Harvard Bioscience Schedules Third Quarter 2026 Earnings Conference Call for November 10, 2026 at 8:00 AM ET
- Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $7.5
- Harvard Bioscience Sees FY2026 Sales $89.147M-$90.877M vs $88.600M Est.
- Harvard Bioscience Sees Q3 Sales $21.000M-$22.600M vs $21.850M Est
- Harvard Bioscience Q2 Adj. EPS $(0.14) Beats $(0.21) Estimate, Sales $22.727M Beat $21.450M Estimate
- Lensar Appoints Michael A. Rossi As Interim CFO Effective May 29, 2026
- Harvard Bioscience Q1 2026 Earnings Call Transcript
- Harvard Bioscience Sees Q2 Sales $20.500M-$22.500M vs $21.900M Est
- Harvard Bioscience Q1 Adj. EPS $(0.33) Beats $(0.62) Estimate, Sales $20.755M Miss $21.200M Estimate
- Earnings Scheduled For May 12, 2026
Your note
Sign in to keep a note on HBIO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COTE JENNIFER | Chief Financial Officer | Stock Award(Grant) | Mar 4, 2024 | 168,738 |
| EADE KATHERINE ANNE | Director | Stock Award(Grant) | May 20, 2024 | 311,126 |
| EDRICK ALAN IAN | Director | Stock Award(Grant) | May 20, 2024 | 273,911 |
| GREEN JAMES W | Chief Executive Officer | Purchase | Jun 12, 2024 | 3,111,090 |
| LOEWALD THOMAS W | Director | Stock Award(Grant) | May 20, 2024 | 295,311 |
| LOY BERTRAND | Director | Stock Award(Grant) | May 20, 2024 | 556,208 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 6.69% | 2,916,176 | 6.12M | Sep 29, 2024 |
| Punch & Associates Investment Management, Inc. | 6.36% | 2,772,700 | 5.82M | Sep 29, 2024 |
| Harvey Partners, LLC | 6.22% | 2,715,000 | 5.70M | Sep 29, 2024 |
| AMH Equity Ltd. | 5.48% | 2,388,868 | 5.02M | Sep 29, 2024 |
| Vanguard Group Inc | 4.94% | 2,154,052 | 4.52M | Sep 29, 2024 |
| Granahan Investment Management LLC | 4.28% | 1,865,429 | 3.92M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.89% | 1,261,693 | 2.65M | Sep 29, 2024 |
| Heartland Value Fund | 2.75% | 1,200,000 | 2.52M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.18% | 952,121 | 2.00M | Oct 30, 2024 |
| Royce Micro-Cap Fund | 1.48% | 647,017 | 1.36M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.33% | 579,986 | 1.22M | Sep 29, 2024 |
| JNL Series Trust-JNL/Multi Manager Small Cap GrowthFd | 1.04% | 453,803 | 952.99K | Sep 29, 2024 |